S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)

Sonoma Pharmaceuticals (SNOA) Earnings Date, Estimates & Call Transcripts

$0.15
0.00 (-1.09%)
(As of 12:12 PM ET)

Earnings Summary

Upcoming
Earnings Date
Jun. 19Estimated
Actual EPS
(Feb. 8)
-$0.06 Beat By $0.15
Consensus EPS
(Feb. 8)
-$0.21
Skip Charts & View Estimated and Actual Earnings Data

SNOA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SNOA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Sonoma Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate:($0.89) EPS
Next Year EPS Consensus Estimate: ($0.45) EPS

SNOA Earnings Date and Information

Sonoma Pharmaceuticals last released its quarterly earnings results on February 8th, 2024. The reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The company earned $3.14 million during the quarter. Sonoma Pharmaceuticals has generated ($0.97) earnings per share over the last year (($0.97) diluted earnings per share). Earnings for Sonoma Pharmaceuticals are expected to grow in the coming year, from ($0.89) to ($0.45) per share. Sonoma Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, June 19th, 2024 based off prior year's report dates.

Sonoma Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
6/19/2024
Estimated)
------- 
2/8/2024Q4 2023($0.21)($0.06)+$0.15($0.04)-$3.14 million
11/13/2023Q3 2023($0.19)($0.20)($0.01)($0.11)-$2.73 million
8/10/2023Q1 2024-($0.29)($0.29)($0.29)-$3.43 million
6/21/2023Q4 2023-($0.23)($0.23)($0.15)-$3.01 million
2/14/2023Q3 2023-($0.50)($0.50)($0.38)-$2.94 million
11/14/2022Q2 2023-($0.19)($0.19)($0.05)-$3.33 million
8/11/2022Q1 2023-($0.29)($0.29)($0.29)-$3.98 million
7/13/2022Q4 2022-($0.95)($0.95)($0.95)-$2.30 million
2/11/2022Q3 2022-($0.31)($0.31)($0.31)-$2.90 million
11/15/2021Q2 2022-($0.04)($0.04)($0.04)-$3.74 million
8/16/2021Q1 2022-($0.52)($0.52)($0.52)-$3.68 million
7/14/2021Q4 2021-($1.64)($1.64)($1.52)-$2.16 million

Sonoma Pharmaceuticals Earnings - Frequently Asked Questions

When is Sonoma Pharmaceuticals's earnings date?

Sonoma Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, June 19th, 2024 based off last year's report dates. Learn more on SNOA's earnings history.

Did Sonoma Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Sonoma Pharmaceuticals (NASDAQ:SNOA) reported ($0.06) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.21) by $0.15. Learn more on analysts' earnings estimate vs. SNOA's actual earnings.

How much revenue does Sonoma Pharmaceuticals generate each year?

Sonoma Pharmaceuticals (NASDAQ:SNOA) has a recorded annual revenue of $13.27 million.

How much profit does Sonoma Pharmaceuticals generate each year?

Sonoma Pharmaceuticals (NASDAQ:SNOA) has a recorded net income of -$5.15 million. SNOA has generated -$0.97 earnings per share over the last four quarters.

What is Sonoma Pharmaceuticals's EPS forecast for next year?

Sonoma Pharmaceuticals's earnings are expected to grow from ($0.89) per share to ($0.45) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:SNOA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners